Scinai Immunotherapeutics Announces Funding and CDMO Growth
Ticker: SCNI · Form: 6-K · Filed: 2025-06-12T00:00:00.000Z
Sentiment: neutral
Topics: funding, cdmo, press-release
TL;DR
Scinai secured new funding and is growing its CDMO biz ahead of BIO Intl Convention.
AI Summary
On June 12, 2025, Scinai Immunotherapeutics Ltd. announced new funding and growth in its Contract Development and Manufacturing Organization (CDMO) business. This announcement was made in anticipation of the BIO International Convention 2025.
Why It Matters
This news signals potential expansion and increased operational capacity for Scinai, which could impact its ability to deliver on future projects and partnerships.
Risk Assessment
Risk Level: low — The filing is a routine report of a press release and does not contain significant new financial or operational risks.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- June 12, 2025 (date) — Date of press release
- BIO International Convention 2025 (event) — Event preceding announcement
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a press release issued by Scinai Immunotherapeutics Ltd. on June 12, 2025, highlighting new funding and CDMO growth.
When was the press release issued?
The press release was issued on June 12, 2025.
What key areas did the press release highlight?
The press release highlighted new funding and growth in Scinai's Contract Development and Manufacturing Organization (CDMO) business.
What event is Scinai anticipating with this announcement?
Scinai is anticipating the BIO International Convention 2025.
Does Scinai file annual reports under Form 20-F or Form 40-F?
Scinai Immunotherapeutics Ltd. files annual reports under Form 20-F.
From the Filing
0001213900-25-053720.txt : 20250612 0001213900-25-053720.hdr.sgml : 20250612 20250612120502 ACCESSION NUMBER: 0001213900-25-053720 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250612 FILED AS OF DATE: 20250612 DATE AS OF CHANGE: 20250612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 251042159 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0245554-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Explanatory Note On June 12, 2025, Scinai Immunotherapeutics Ltd. issued a press release highlighting new funding and CDMO growth ahead of the BIO International Convention 2025. A copy of the press release is furnished herewith as Exhibit 99.1. This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078 and File No. 333-276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit Index Exhibit No. Description 99.1 Press release dated June 12, 2025 . 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: June 12, 2025 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2 EX-99.1 2 ea024555401ex99-1_scinai.htm PRESS RELEASE DATED JUNE 12, 2025 Exhibit 99.1 Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference JERUSALEM, June 12, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering biologics CDMO services through its Scinai BioServices unit, today announced CEO Amir Reichman’s participation in the BIO International Convention 2025 (June 16–19, Boston). The company will leverage the event to showcase its recent financial, operational, and strategic advances to prospective partners and investors. Recent SEPA Funding Enhances Operational Flexibility Last week, Scinai raised $1.38 million in gross proceeds through drawdowns under its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. The funding was executed at a volume-weighted average price of approximately $3.03 per ADS, reflecting a 3% discount to market, and was completed without any warrants, fees, or additional dilution mechanisms. The proceeds strengthen Scinai’s balance shee